Trevi Therapeutics, Inc. Investing Cash Flow
Trevi Therapeutics, Inc. (TRVI) reported Investing Cash Flow of -$95.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$112.04M.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $16.96M.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$30.61M.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$50.94M, a 764.38% decline year-over-year.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$94.11M.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$21.53M, a 136.23% decline from fiscal 2023.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $59.43M.
- Trevi Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$107.37M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$112.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$95.07M 10-Q · filed 2026-08-06 | -$125.68M derived: sum of 3 quarters · filed 2026-08-06 | -$176.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $16.96M 10-Q · filed 2026-05-05 | -$13.64M derived: sum of 2 quarters · filed 2026-05-05 | -$64.58M derived: sum of 3 quarters · filed 2026-05-05 | -$67.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$30.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$81.55M derived: sum of 2 quarters · filed 2026-03-17 | -$84.16M derived: sum of 3 quarters · filed 2026-08-06 | -$94.11M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$50.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$53.55M derived: sum of 2 quarters · filed 2026-08-06 | -$63.50M 10-Q · filed 2025-11-13 | -$87.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$12.56M 10-Q · filed 2026-08-06 | -$36.43M derived: sum of 3 quarters · filed 2026-08-06 | -$28.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$9.95M 10-Q · filed 2026-05-05 | -$33.82M derived: sum of 2 quarters · filed 2026-05-05 | -$26.16M derived: sum of 3 quarters · filed 2026-05-05 | -$23.39M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$23.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$16.20M derived: sum of 2 quarters · filed 2026-03-17 | -$13.44M derived: sum of 3 quarters · filed 2026-03-17 | -$21.53M 10-K · filed 2026-03-17 |
| 2024-09-30 | $7.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.44M derived: sum of 2 quarters · filed 2025-11-13 | $2.34M 10-Q · filed 2025-11-13 | $15.19M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$5.32M 10-Q · filed 2025-08-07 | $7.52M derived: sum of 3 quarters · filed 2025-08-07 | $25.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$8.09M 10-Q · filed 2025-05-08 | $4.75M derived: sum of 2 quarters · filed 2025-05-08 | $22.74M derived: sum of 3 quarters · filed 2025-05-08 | $42.38M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $12.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $30.83M derived: sum of 2 quarters · filed 2025-03-18 | $50.47M derived: sum of 3 quarters · filed 2025-03-18 | $59.43M 10-K · filed 2025-03-18 |
| 2023-09-30 | $17.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $37.62M derived: sum of 2 quarters · filed 2024-11-06 | $46.58M 10-Q · filed 2024-11-06 | -$1.72M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $19.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $28.60M 10-Q · filed 2024-08-08 | -$19.70M derived: sum of 3 quarters · filed 2024-08-08 | -$24.55M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $8.96M 10-Q · filed 2024-05-07 | -$39.34M derived: sum of 2 quarters · filed 2024-05-07 | -$44.19M derived: sum of 3 quarters · filed 2024-05-07 | |
| 2022-12-31 | -$48.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$53.16M derived: sum of 2 quarters · filed 2024-03-20 | -$107.37M 10-K · filed 2024-03-20 | |
| 2022-09-30 | -$4.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$59.07M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | -$54.22M 10-Q · filed 2023-08-10 | |||
| 2020-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$20.00K derived: sum of 2 quarters · filed 2022-03-17 | -$32.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$27.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$12.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | -$9.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | -$9.00K 10-Q · filed 2020-11-12 | -$101.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$9.00K 10-Q · filed 2020-08-13 | -$101.00K derived: sum of 3 quarters · filed 2020-08-13 | -$100.00K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$9.00K 10-Q · filed 2020-05-07 | -$101.00K derived: sum of 2 quarters · filed 2020-05-07 | -$100.00K derived: sum of 3 quarters · filed 2020-05-07 | -$110.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$91.00K derived: sum of 2 quarters · filed 2020-03-16 | -$101.00K derived: sum of 3 quarters · filed 2020-03-16 | -$158.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$9.00K derived: sum of 2 quarters · filed 2019-11-14 | -$66.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$67.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$57.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |